OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding

Company Overview - OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED) [1][6] - The company's ordinary shares are listed on the NASDAQ Capital Market [6] - OKYO Pharma is currently evaluating its lead program, OK-101, in Phase 2 trials for both NCP and DED [5][6] Funding and Financials - OKYO Pharma has received $1.4 million in non-dilutive funding, which will be used to advance its research and development initiatives [1][2] - The funding is strategically allocated to support the company's lead program, OK-101, particularly for the treatment of NCP [2] - This financial boost strengthens the company's ability to advance its innovative pipeline without diluting shareholder value [1][3] Product Pipeline - OK-101 is a lipid-conjugated chemerin peptide agonist targeting the ChemR23 G-protein coupled receptor, found on immune cells, neurons, and glial cells in the eye [5] - The drug candidate has shown anti-inflammatory and pain-reducing activities in mouse models of DED and NCP [5] - OK-101 has demonstrated clear statistical significance in multiple endpoints in a Phase 2 trial for DED and is currently being evaluated in a Phase 2 trial for NCP [5][6] Market and Medical Need - NCP is a severe ocular condition without an FDA-approved therapy, currently treated with off-label topical and systemic treatments [4] - DED represents a multi-billion-dollar market, highlighting the significant commercial potential for OKYO Pharma's therapies [1] - The company is addressing critical unmet medical needs in ophthalmology, particularly for patients suffering from chronic and debilitating conditions [4][5] Leadership and Contact Information - Dr Gary S Jacob serves as the CEO of OKYO Pharma [3] - For business development and investor relations, Paul Spencer can be contacted at +44 (0)20 7495 2379 [8]